Who are nitric oxide gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inomax, Topical Nitroglycerine, Monoket Pill, Topical NO, Crossover iNO, Nicardipine + Verapamil + Nitroglycerin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitric-oxide-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

nitric oxide gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nitric oxide gel (nitric oxide gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical vasodilator. Area: Dermatology / Wound Care.

marketed Topical vasodilator Soluble guanylate cyclase Dermatology / Wound Care Small molecule Live · refreshed every 30 min

Target snapshot

nitric oxide gel (nitric oxide gel) — China Medical University Hospital. Nitric oxide gel delivers nitric oxide directly to tissue to promote vasodilation, improve blood flow, and enhance wound healing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nitric oxide gel TARGET	nitric oxide gel	China Medical University Hospital	marketed	Topical vasodilator	Soluble guanylate cyclase
Inomax	NITRIC OXIDE	Vero Biotech Inc	marketed	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Topical Nitroglycerine	Topical Nitroglycerine	Aultman Health Foundation	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Monoket Pill	Monoket Pill	Ohio State University	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Topical NO	Topical NO	University of Aberdeen	marketed	Nitric oxide donor	Nitric oxide pathway; soluble guanylate cyclase
Crossover iNO	Crossover iNO	University of Florida	marketed	Inhaled vasodilator	Soluble guanylate cyclase (via nitric oxide signaling)
Nicardipine + Verapamil + Nitroglycerin	Nicardipine + Verapamil + Nitroglycerin	Peng Roc Chen, MD	marketed	Combination antihypertensive/antianginal (calcium channel blockers + nitrate)	L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical vasodilator class)

China Medical University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nitric oxide gel — Competitive Intelligence Brief. https://druglandscape.com/ci/nitric-oxide-gel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing